Search Results
Nov 10, 2025, 09:02 ET MOTIVE HEALTH LAUNCHES BREAKTHROUGH LOWER BACK THERAPY THAT DELIVERS LASTING RELIEF
sessions. "Lower back discomfort is one of the most common and limiting musculoskeletal conditions we see," said Dr. Struan Coleman, MD, Ph.D., Sports Medicine Surgeon at Hospital for Special Surgery and Co-Founder of Motive Health. "By strengthening the deep muscles that support the spine,
More news about: Motive Health, Inc.
Nov 10, 2025, 09:01 ET Nemours Children's Health Launches Nation's First Pediatric Advanced Care at Home
Home is an extension of our Whole Child Health approach — care designed to support children where they live, learn, and grow," said R. Lawrence Moss, MD, FACS, FAAP, President and CEO of Nemours Children's Health. "This is an entirely new model of care that brings children home, keeps families together,
More news about: Nemours Children's Health
Nov 10, 2025, 08:46 ET Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
Muthiah MD, Cheng Han N, Sanyal AJ. A clinical overview of non-alcoholic fatty liver disease: a guide to diagnosis, the clinical features, and complications—What
More news about: NOVO NORDISK INC.
Nov 10, 2025, 08:45 ET Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
Muthiah MD, Cheng Han N, Sanyal AJ. A clinical overview of non-alcoholic fatty liver disease: a guide to diagnosis, the clinical features, and complications—What
More news about: NOVO NORDISK INC.
Nov 10, 2025, 08:33 ET ATIXA and NABITA Announce 2026 Training and Event Schedule
training, certification, connection, and collaboration. October 12-17, 2026, Baltimore, MDATIXA's 15th Annual Conference and NABITA's 18th Annual Conference return to Baltimore, serving as the premier national
More news about: ATIXA and NABITA
Nov 10, 2025, 08:32 ET Rajani MD Debuts the New PlasmaGLO™ HALO LED Face, Neck, & Hair Mask -- The Next Generation of At-Home Beauty Tech
Rajani MD, the innovative aesthetics brand founded by globally recognized physician and educator Dr. Anil Rajani, MD, proudly announces the launch of the new PlasmaGLO HALO Mask — an advanced device
More news about: Rajani MD
Nov 10, 2025, 08:30 ET Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B
encouraged to see that the difference in HBsAg seroclearance rates observed at EOT was maintained through 24 weeks of follow-up." said David Margolis, MD, Chief Medical Officer of Brii Bio. "These results support BRII-179's potential to deliver more rapid and durable HBsAg loss and potentially enable a
More news about: Brii Biosciences Limited
Nov 10, 2025, 08:00 ET Vexev's VxWave System Successfully Meets Clinical Endpoints in Landmark Study Evaluating Robotic Ultrasound Scanning for Mapping Vascular Access at U.S. Renal Care Dialysis Clinics
success of the CANSCAN Trial confirms that standardized, high-quality, point-of-care vascular assessment may now be achievable," said Shannon Thomas, MD, Chief Medical Officer, Vexev. "The trial represents a significant step towards the future of standardized vascular assessment across the globe, allowing
More news about: Vexev
Nov 10, 2025, 08:00 ET KTL Solutions and RADICL Partner to Deliver Enhanced Cybersecurity and vSOC Services for Government Contractors
FREDERICK, Md., Nov. 10, 2025 /PRNewswire/ -- KTL Solutions and RADICL have announced a new partnership focused on helping government contractors and regulated organizations strengthen cybersecurity
More news about: KTL Solutions, Inc
Nov 10, 2025, 07:30 ET ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
in r/r follicular lymphoma (FL) presented at the 22nd International Workshop on Non-Hodgkin Lymphoma (iwNHL). Juan Pablo Alderuccio, MD, Clinical Site Disease Group Leader, Lymphoma Section, at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine,
More news about: ADC Therapeutics SA
Nov 10, 2025, 07:06 ET Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage
"The clinical progress of SIM0278 significantly strengthens Simcere's leading position in the field of autoimmune diseases." Said Dr Aik H Goh, MD , Chief Medical Officer of Simcere," The initiation of Phase II clinical trials also marks a significant step forward in the project's global clinical
More news about: Simcere Pharmaceutical Group Limited
Nov 10, 2025, 07:00 ET enCore Energy Reports Q3 2025 Financial Results; Uranium Extraction Advances in South Texas
SEC and on SEDAR+, particularly those described in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and annual information from and MD&A. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with assumptions regarding
More news about: enCore Energy Corp.
Nov 10, 2025, 07:00 ET Ceva, Inc. Announces Third Quarter 2025 Financial Results
in wireless IP ROCKVILLE, Md., Nov. 10, 2025 /PRNewswire/ -- Ceva, Inc. (NASDAQ: CEVA), the leading licensor of silicon and software IP for
More news about: Ceva, Inc.
Nov 10, 2025, 06:30 ET CGI awarded £250-million Enterprise Integration Services contract with His Majesty's Revenue and Customs in the UK
titled Risk Environment of CGI's annual and quarterly MD&A, which is incorporated by reference in this cautionary statement. We also caution readers that the above-mentioned risks and the risks disclosed in CGI's annual and quarterly MD&A and other documents and filings are not the only ones
More news about: CGI Inc.
Nov 10, 2025, 06:00 ET A 0% Down VA Loan Can Put Veterans in a Home 4.4 Years Sooner
Baltimore-Columbia-Towson, MD
More news about: Realtor.com
Nov 10, 2025, 04:46 ET Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage
"The clinical progress of SIM0278 significantly strengthens Simcere's leading position in the field of autoimmune diseases." Said Dr Aik H Goh, MD, Chief Medical Officer of Simcere," The initiation of Phase II clinical trials also marks a significant step forward in the project's global clinical
More news about: Simcere Pharmaceutical Group Limited
Nov 09, 2025, 23:00 ET Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
from atherogenic lipoproteins. The data were presented today at the American Heart Association 2025 Scientific Sessions by Dr.Alex DePaoli, MD, CMO. The randomized, placebo-controlled Single Ascending Dose (SAD) study in volunteers with baseline TG >80 mg/dl showed
More news about: Rona Therapeutics
Nov 09, 2025, 23:00 ET Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
from atherogenic lipoproteins. The data were presented today at the American Heart Association 2025 Scientific Sessions by Dr.Alex DePaoli, MD, CMO. The randomized, placebo-controlled Single Ascending Dose (SAD) study in volunteers with baseline TG >80 mg/dl showed
More news about: Rona Therapeutics
Nov 09, 2025, 19:00 ET Innovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting
more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard
More news about: Innovent Biologics
Nov 09, 2025, 14:50 ET Marriott International Announces Termination of Agreement with Sonder
BETHESDA, Md., Nov. 9, 2025 /PRNewswire/ -- Marriott International, Inc. (NASDAQ: MAR) today announced that its licensing agreement with Sonder Holdings Inc. (NASDAQ: SOND, "Sonder") is no
More news about: Marriott International, Inc.
Nov 09, 2025, 10:03 ET Marriott International Provides Financial Outlook Update Following Termination of Agreement with Sonder
BETHESDA, Md., Nov. 9, 2025 /PRNewswire/ -- Marriott International, Inc. (NASDAQ: MAR) announced today that its licensing agreement with Sonder Holdings Inc. (NASDAQ: SOND, "Sonder") was no
More news about: Marriott International, Inc.
Nov 09, 2025, 10:00 ET Marriott International Announces Termination of Agreement with Sonder
BETHESDA, Md., Nov. 9, 2025 /PRNewswire/ -- Marriott International, Inc. (NASDAQ: MAR) today announced that its licensing agreement with Sonder Holdings Inc. (NASDAQ: SOND, "Sonder") is no
More news about: Marriott International, Inc.
Nov 09, 2025, 08:58 ET Silent Beacon Joins Forces with Mental Health Cooperative to Equip Mental Health Crisis Workers with Wearable Panic Buttons
ROCKVILLE, Md., Nov. 9, 2025 /PRNewswire/ --
More news about: Silent Beacon
Nov 08, 2025, 11:00 ET Robbins Geller Rudman & Dowd LLP Announces that CarMax, Inc. (KMX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
2, 2026 to seek appointment as lead plaintiff of the CarMax class action lawsuit. Captioned Cap v. CarMax, Inc., No. 25-cv-03602 (D. Md.), the CarMax class action lawsuit charges CarMax as well as certain of CarMax' top executives with violations of the Securities Exchange Act of
More news about: Robbins Geller Rudman & Dowd LLP
Nov 08, 2025, 10:15 ET AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
their lipid regimen substantially reduces their risk of MACE," said Marc S. Sabatine, M.D., M.P.H., Chair of the TIMI Study Group and the Lewis Dexter, MD, Endowed Chair in Cardiovascular Medicine at Brigham and Women's Hospital. "In both FOURIER and VESALIUS-CV, patients in the evolocumab arm achieved median
More news about: Amgen